{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:40:04Z","timestamp":1777876804242,"version":"3.51.4"},"reference-count":0,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"Summary<\/jats:title>\n \n What is this summary about?<\/jats:bold>\n <\/jats:p>\n \n This summary describes the results of a clinical study that compared two different doses of a treatment, called\n inotuzumab ozogamicin<\/jats:bold>\n (inotuzumab for short), for\n acute lymphoblastic leukemia<\/jats:bold>\n (ALL for short). This summary describes the results for people aged 18 years and older who took part in the study.\n <\/jats:p>\n \n Why was this study done?<\/jats:bold>\n <\/jats:p>\n \n People who took part in the study had a higher risk of developing a side effect called\n sinusoidal obstruction syndrome<\/jats:bold>\n (SOS for short), also known as veno-occlusive disease (VOD for short), which is a rare condition where some of the small blood vessels in the liver become blocked. Researchers wanted to find out if receiving a lower dose than the recommended dose of inotuzumab reduced the likelihood of people developing SOS after a stem cell transplant. Researchers wanted to find out if a lower dose of inotuzumab would also impact the efficacy (how well inotuzumab works to treat ALL) in people with ALL and what other side effects occurred.\n <\/jats:p>","DOI":"10.1177\/17588359251370948","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:51:30Z","timestamp":1759999890000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparing two different doses of inotuzumab ozogamicin treatment in adult patients with acute lymphoblastic leukemia: a plain language summary of publication"],"prefix":"10.1177","volume":"17","author":[{"given":"Muhit","family":"\u00d6zcan","sequence":"first","affiliation":[{"name":"Department of Hematology, Ankara University School of Medicine, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan D.","family":"Cassaday","sequence":"additional","affiliation":[{"name":"University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Zarzycka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Transplantology, Medical University of Gda\u0144sk, Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Vandendries","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[{"name":"Pfizer Inc., La Jolla, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra","family":"Nieto","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatih","family":"Demirkan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Dokuz Eylul University, Izmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[{"name":"Hematology Department, La Fe University and Polytechnic Hospital, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fevzi","family":"Altuntas","sequence":"additional","affiliation":[{"name":"Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,10,9]]},"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251370948","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359251370948","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251370948","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:33:16Z","timestamp":1777588396000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359251370948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":0,"alternative-id":["10.1177\/17588359251370948"],"URL":"https:\/\/doi.org\/10.1177\/17588359251370948","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"article-number":"17588359251370948"}}